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Abstract
Pseudomonas aeruginosa lung infection is difficult to eradicate due to the multiple 
(intrinsic and acquired) antibiotic resistance of bacteria and to their ability to pro-
duce a thick biofilm. Antibiotic treatment is hampered by poor antibiotic diffusion, 
efflux pump overexpression and the development of a persistent subpopulation 
with low metabolic activity. This is a cause for special concern in Cystic Fibrosis 
(CF) patients, where P. aeruginosa lung infection is the chief cause of morbidity 
and mortality. Combined tobramycin-ciprofloxacin treatment is routinely adopted 
due to the low frequency of resistant strains and its ostensible ability to control the 
infection. Nevertheless, symptoms usually recur, mainly due to the antibiotic per-
sisters, which are difficult to detect in routine cultural microbiological assays. This 
chapter describes the issues involved in the microbiological diagnosis of P. aerugi-
nosa lung infection in CF patients and the possible role of subinhibitory antibiotic 
concentrations in persister development and infection recurrence.
Keywords: Pseudomonas aeruginosa, biofilms, antibiotic resistance,  
bacterial persisters, viable but non-culturable forms, infection recurrence
1. Introduction
Infectious biofilms have long been recognized as a severe clinical problem due 
to their tolerance to antimicrobials and their successful evasion of host defenses 
[1]. Their eradication is hampered by a variety of factors that are related to the 
sessile lifestyle and high cell density typical of biofilms, chiefly the poor diffusion 
of antibiotics and immune cells, the selection of antibiotic-resistant mutants, the 
development of intrinsic antibiotic-resistant phenotypes, like small colony variants 
(SCVs), and the spread of resistance genes among the bacterial populations through 
horizontal gene transfer (HGT) events. The problem is compounded by the devel-
opment of antibiotic-unresponsive dormant cells, which upon reaching the late 
stage of dormancy can become non-culturable [2–4], thus escaping detection by 
routine culture-based assays [5, 6]. The difficulty of eradicating bacterial biofilms is 
a key factor in recurrent and chronic infections [1, 7, 8].
The opportunistic pathogen Pseudomonas aeruginosa is one of the bacteria most 
frequently involved in biofilm-related infections. Although most strains are environ-
mental, the pathogen can live in symbiosis with a variety of hosts including plants, 
Pseudomonas aeruginosa - Biofilm Formation, Infections and Treatments
2
insects and animals. In humans it is an important nosocomial pathogen responsible 
for a variety of infections that have a strong tendency to recur, particularly in burn 
patients and in those with lung involvement. Like other opportunistic pathogens, it 
typically affects immunocompromised individuals [9]. However, the subjects most 
prone to develop P. aeruginosa infection are patients with cystic fibrosis (CF).
2. P. aeruginosa biofilms and lung infection in cystic fibrosis
2.1 P. aeruginosa biofilms and antibiotic resistance
The ubiquitous presence of P. aeruginosa, its prevalence and persistence in 
clinical settings and its intrinsic resistance to therapeutics are underpinned by 
an extraordinary arsenal of response mechanisms [10]. In particular, bacteria are 
protected by biofilms from adverse environmental conditions like phagocytosis, 
oxidative stress, nutrient/oxygen restriction, metabolic waste accumulation and 
antimicrobial agents [1, 11]. The matrix – which provides a favorable niche for 
intense cell–cell interaction and communication and a reservoir of metabolic 
substances, nutrients and energy [12] – accounts for 90% of the dry weight of the 
biofilm mass. Its main constituents are extracellular polysaccharides, proteins, 
extracellular DNA (eDNA), lipids, especially rhamnolipids, and other secreted 
molecules, such as the siderophores pyoverdine and pyocheclin, pyocyanin and 
phenazines. The production of all these components is highly regulated by quorum 
sensing (QS). P. aeruginosa biofilm development is characterized by the produc-
tion of large amounts of three types of extracellular polysaccharides: Psl, Pel 
and alginate. Psl and Pel are the main constituents of the extracellular matrix in 
non-mucoid strains and are involved in the early stages of biofilm formation and 
in cell–cell interactions, whereas alginate overproduction is associated with the 
mucoid phenotype, the hallmark of chronic infection, and is indicative of disease 
progression and long-term persistence.
Biofilm development is held to be a differentiation process – activated in 
response to a variety of environmental stimuli – that alters pathogen behavior and 
results in the adoption of a sessile lifestyle [13]. Biofilms are characterized by an 
intricate regulation network that induces the development of different bacterial 
subpopulations and the emergence of antibiotic-resistant variants, which are a 
typical trait of P. aeruginosa biofilms [14]. The heterogeneity of the biofilm bacterial 
population is associated with the presence of niches with distinctive environmental 
characteristics that modulate gene expression patterns [15].
Biofilm formation is regulated by a number of redundant mechanisms of which QS 
is the most widely investigated. Four different QS systems, Las, Rhl, Pqs and Iqs, each 
characterized by a specific signal molecule and a receptor protein, have been described 
in P. aeruginosa. QS systems are involved in the regulation of several metabolic and 
pathogenic pathways that have a significant role in bacterial fitness in the environment 
as well as in the host. Their interplay is governed by a complicated hierarchical net-
work, where the Las system directly regulates the Pqs and the Rhl systems [15].
Additional regulator systems, which sense the changes in the extracellular 
environment and regulate gene expression accordingly, also seem to be key factors 
in biofilm population dynamics. The best known is the Gac/Rsm system, which is 
the main factor controlling the switch from the planktonic to the sessile lifestyle 
in P. aeruginosa [13]. It encompasses two proteins, GacS/GacR, which sense and 
respond to environmental stimuli, promoting the synthesis of two small RNAs, 
RsmZ and RsmY, which bind and sequester the post-transcriptional regulator RsmA 
[16]. It induces the expression of virulence factors and of other genes playing roles 
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in colonization and acute infection processes, such as the genes involved in motility 
(synthesis of pili) and in the type III secretion system; at the same time, it represses 
some genes implicated in chronic infections, such as those encoding the production 
of alginate and other exopolysaccharides, which constitute the biofilm matrix. RsmA 
sequestration seems to be a central mechanism in the shift from the planktonic to 
the biofilm lifestyle [16]. The second messenger c-di-GMP acts through an alterna-
tive regulation pathway and seems to promote biofilm development by a variety of 
routes: repression of motility-related genes, exopolysaccharide overproduction and 
expression of the adhesin CdrA [17, 18]. RsmA and c-di-GMP share overlapping 
targets and indirectly regulate each other with antagonistic effects, supporting the 
notion of a redundant system [19]. The fact that the c-di-GMP positively regulated 
efflux pump overexpression through brlR induction highlights the importance of the 
messenger in the development of antibiotic resistance/persistence phenotypes [20].
In sessile cells, the action of antibiotics is contrasted by a variety of mecha-
nisms that make them less susceptible to antimicrobials than planktonic cells [21]. 
Notably, the biofilm matrix acts as a barrier, limiting the diffusion of toxic com-
pounds [22]; in particular, binding to eDNA prevents positively charged antibiot-
ics such as aminoglycosides from penetrating the bacterial cells [23]. Moreover, 
in biofilm-growing P. aeruginosa a wide range of resistance determinants are 
expressed or upregulated in a biofilm-specific manner [24]. Indeed, overexpres-
sion of the efflux pumps – particularly MexAB-OprM and MexXY-OprM – is the 
main cause of the multiple antibiotic-resistant phenotype [25] that characterizes 
chronic P. aeruginosa infection and contributes to the failure of its eradication in 
CF patients [26, 27]. The mexAB-oprM operon is upregulated in biofilms resistant 
to azithromycin [28] and fluoroquinolones [29] and also seems to be involved in 
colistin tolerance, which has been described in actively growing P. aeruginosa cells 
[30]. MexXY-OprM is the main aminoglycoside resistance determinant. It is a 
typical example of inducible adaptive resistance [31]; this is also demonstrated by 
the frequent recovery, from chronic patients, of strains bearing mutations in mexZ, 
a repressor gene of the mex-XY operon, which is considered as a mutation hotspot 
in biofilm-growing P. aeruginosa and a typical example of convergent evolution 
of different CF clonal lineages [32, 33]. Other remarkable examples of antibiotic 
resistance associated with biofilm growth are endogenous AmpC ß-lactamase 
overexpression and upregulation of the ndvB gene [34]; the latter is involved in bio-
film-specific synthesis of cyclic glucans, which are responsible for aminoglycoside 
binding and trapping [35]. Finally, the biofilm is an ideal environment for HGT 
events [8], which contribute to the spread of resistance determinants. Conjugation 
events are favored by close contact between cells of different strains and/or spe-
cies [36]; moreover, it has recently been suggested that P. aeruginosa biofilms can 
achieve a natural competence to acquire both genomic and plasmid DNA [37]. 
This is a cause of particular concern for chronic CF patients, whose lungs are often 
colonized by different antibiotic-resistant strains, a condition that has the potential 
to give rise to multidrug resistance [38].
2.2 P. aeruginosa CF lung infection
Cystic Fibrosis is a genetic autosomic disease due to mutations in the cystic 
fibrosis transmembrane conductance regulator (CFTR) gene, which involve a wide 
range of dysfunctions that alter the airway environment and increase susceptibility 
to bacterial respiratory infections. CFTR gene dysfunction affects epithelial cells, the 
pancreas (malabsorption), the liver (biliary cirrhosis), the sweat glands (heat shock) 
and the vas deferens (infertility). Patients with late disease suffer from bronchiec-
tasis, small airway obstruction and progressive respiratory impairment [39]. CF is 
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characterized by recurrent pulmonary exacerbations. Worsening of the chronic lung 
infection symptoms (particularly cough and sputum production), increased bacterial 
load and inflammation and, often, a reduction in FEV1 (forced respiratory volume in 
1 second) impair lung function hence quality of life and overall survival.
The identification of effective treatments requires a greater understanding of the 
factors underpinning the exacerbations. Notably, the lung of CF patients is initially 
colonized by Haemophilus influenzae and Staphylococcus aureus; then, patients 
gradually become susceptible to infection with a variety of environmental Gram-
negative bacteria carrying a broad range of constitutive and acquired antibiotic 
resistance determinants [39]. P. aeruginosa is the main pathogen triggering airway 
inflammation and the leading cause of CF morbidity and mortality [40]. Most CF 
patients are susceptible to P. aeruginosa respiratory infections from infancy. The 
30% of them acquire a strain from the environment resulting in acute infections in 
the first year of life, this rate increases to about 50% before turning 3 years, while 
mucoid phenotype and chronic infection usually raise from 3 to 16 years [10].
Lung colonization generally involves alternate asymptomatic periods and 
relapses with progressive tissue deterioration that eventually lead to lung failure and 
to premature death. Over the years P. aeruginosa develops multiple phenotypic vari-
ants such as SCVs, mucoid and persistent forms. In particular, SCVs are typically 
isolated from the lungs of chronic CF patients. They are small (1–3 mm in diameter) 
usually non-motile and resistant to several classes of antibiotics; produce high 
amounts of exopolysaccharide and form biofilms that strongly adhere to surfaces 
[41]. In vitro and in vivo tests have demonstrated that exposure to sublethal concen-
trations of antibiotics, such as aminoglycosides, selects for SCVs. In CF patients, 
prolonged persistent infection, deterioration of pulmonary function and increased 
antibiotic resistance all correlate with SCVs detection in sputum [41].
P. aeruginosa adaptation to the CF lung environment ultimately results in a 
mucoid phenotype, a conversion first described by Lam and colleagues [42], which 
may take several months to years. The mucoid material has subsequently been iden-
tified as alginate. In mucoid strains, alginate may favor adhesion to lung epithelial 
cells, thereby inhibiting clearance. Nutrient restriction, dehydration and subopti-
mal antibiotic concentrations may result in mucoidity [7, 43]. Host inflammation 
responses are also believed to contribute to mucoid conversion, a hypothesis that is 
supported by the absence of mucoid variants among environmental isolates [44].
3.  Persister development: antibiotic failure and microbiological 
diagnosis
3.1 Persistent and viable but non-culturable (VBNC) bacterial forms
P. aeruginosa lung infections tend to be recurrent. Relapses are chiefly due to 
the development of persisters, bacterial forms that are unsusceptible to antibiotics 
and often difficult to detect by routine microbiological assays. Persistence has been 
defined as “the ability of a subset of the bacterial population to survive to a bacteri-
cidal antibiotic concentration” [45]. Survival is demonstrated by bacterial growth 
in culture once the stressor, i.e. antibiotic concentrations several times higher than 
the minimal inhibitory concentration (MIC), has been removed and nutrients 
have been restored. Accordingly, the main features distinguishing persisters from 
resistant cells are the inability of the former cells to grow in presence of antibiotics, 
though viable and metabolically active, and the lack of heritability [45].
Persisters have been considered as dormant cells that are unaffected by antibiot-
ics [46]. However, lack of significant growth or metabolic activity does not equal 
5
Pseudomonas aeruginosa Biofilm Lung Infection in Cystic Fibrosis: The Challenge of Persisters
DOI: http://dx.doi.org/10.5772/intechopen.95590
persistence, since the majority (> 99%) of dormant subpopulations are not true 
persisters. Persistence is a far more complex condition than dormancy [47], it 
shows an intense metabolic activity despite cell failure to grow or divide. Indeed, 
starvation-induced persisters produced more ATP per mol of carbon source con-
sumed than nutrient supplied cells did [48]. Accordingly, persister cells seem to 
be able to catabolize carbon sources, which results in increased electron transport 
chain activity and membrane potential and increased aminoglycoside uptake [49]. 
However, although bacterial metabolic processes and persistence are closely related, 
the mechanisms involved are largely unclear [50].
Antibiotic persistence is not to be confused with antibiotic tolerance. In particu-
lar, whereas tolerance involves the whole bacterial population, persistence regards 
only a subset of specialized cells. Moreover, tolerant cells are killed, even if more 
slowly than susceptible cells, by high antibiotic doses while persisters are main-
tained over time (Figure 1). Notably, however, the two cell types share the same 
MIC as susceptible cells [45].
Two types of persisters have been described to date: stochastic and triggered. 
The former cells constitute a small subpopulation that can be found in all bacterial 
cultures, even in exponentially growing ones, whereas the latter are induced by 
environmental as well as host-related stressors. Unfavorable environmental condi-
tions, e.g. nutrient and oxygen depletion, catabolite accumulation and suboptimal 
pH, which can induce persistence, can occur in the lungs of CF patients, especially 
in the deepest layers of P. aeruginosa biofilms [51]. Repeated antibiotic treatment 
directed at eradicating chronic infection can contribute to the induction of these 
specialized bacterial forms [26].
VBNC cells are dormant forms described in several bacterial species, including 
P. aeruginosa. They are characterized by the inability to grow on bacteriological 
media despite the presence of metabolic activity [52]. VBNC cells share several 
features with persisters, including a number of inducing factors of which the most 
common are starvation, oxidative stress, suboptimal salinity and pH and low 
temperature [52]. Moreover, both phenotypes are highly resilient to antimicrobials. 
These similarities have led some researchers to conclude that “persister and VBNC 
cells actually represent subsequent stages of the same cycle of dormancy, adopted 
by non-sporulating bacteria to survive unfavorable conditions” [52]. According to 
this theory, stress exposure would induce the development of persisters, which in 
case of prolonged exposure would turn into VBNC cells, whereas stressor removal 
Figure 1. 
Behavior of susceptible, resistant, tolerant and persistent bacterial subpopulations treated with antibiotic 
concentrations exceeding the MIC. CFU: Colony forming unit.
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and nutrient restoration would involve recovery of the full metabolic state typical 
of exponential growth [52, 53]. Unlike culturable persisters, VBNC cells can regain 
culturability only through the action of specific activators (Figure 2), a phenom-
enon known as resuscitation [54]. The activators can be specific for the bacterial 
species and even for a single strain; while not completely understood they seem 
easily found in vivo [54].
3.2 VBNC P. aeruginosa and issues related to the diagnosis of CF lung infection
In CF patients, the microbiological diagnosis of P. aeruginosa lung infection is still 
performed by culture-based assays, which cannot detect VBNC cells [6]. Such assays 
involve microorganism isolation using rich (Columbia blood or chocolate) and selec-
tive (MacConkey or Pseudomonas) agar followed by isolate identification by biochem-
ical or mass spectrometry analysis [55, 56]. Though effective in diagnosing primary 
colonization and pulmonary exacerbations, these methods suffer from considerable 
limitations, first and foremost poor sensitivity, due to the multiple phenotypic variants 
found in P. aeruginosa isolated from chronic CF biofilm-related infections [57].
A variety of stressors, principally nutrient depletion, oxidative and osmotic 
stress, an acid pH, a strong immune response and the presence of subinhibitory 
antibiotic concentrations [51, 58], make the CF lung an unfavorable environment 
for P. aeruginosa. The bacterial response involves the development of different 
phenotypes. The best known is the mucoid phenotype [59], alongside the loss of 
motility and pigmentation [60], the formation of auxotrophic variants and SCVs 
[61]. All these phenotypes are characterized by slow growth, which hampers 
culture-based diagnosis. However, the main problem is detecting VBNC cells. These 
cells – albeit not necessarily virulent – given suitable conditions can revert to full 
metabolically active forms capable of quick duplication and full virulence [54], 
which trigger a new infection. Developing a diagnostic technique that detects these 
forms is therefore critical to forecast symptom relapse and start early treatment.
3.3 The multifaceted role of antibiotics
Antibiotic treatment can play two different roles as regards persistent cells: it can 
either select a pre-existing persistent subpopulation or induce the persistent phe-
notype [45]. The hypothesis has also been advanced that antibiotics exert a biphasic 
dose-dependent action, i.e. inhibition of bacterial growth at high (≥ the MIC) doses 
Figure 2. 
Differences between culturable persistent and VBNC cells after stressor removal and nutrient restoration. 
Whereas persistent cells quickly begin to grow and divide again, VBNC cells require exposure to a growth 
activator (the resuscitation-promoting factor) before regaining full metabolic activity and doubling ability. The 
progeny of both cell types will contain a mixed population as the starting culture.
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and stimulation of a specific bacterial response by acting as a molecular signal at 
low concentrations (< the MIC), a phenomenon known as hormesis [62].
Failed infection eradication even after prolonged antibiotic treatment is a major 
clinical problem in patients with microbial biofilms. Antibiotic unresponsiveness 
has been explained by poor drug penetration in the biofilm matrix and by the 
development of dormant/persistent cells in the deepest biofilm layers [22]. Since 
low antibiotic concentrations are probably found for extended periods in the lung 
of CF patients with intermittent/chronic infection, who undergo repeated antibiotic 
treatment, the development of persistent forms is likely to be stimulated by the 
drugs themselves. Evidence to this effect has been reported for different classes of 
antibiotics, including quinolones and aminoglycosides, although more comprehen-
sive investigations are required to draw firm conclusions.
4.  P. aeruginosa VBNC cell detection and quantification in CF respiratory 
samples
4.1 Total live cell detection strategies
Given the wide phenotypic variability of P. aeruginosa, encompassing difficult-to 
grow phenotypes, several culture-independent approaches have been devised to 
provide reliable infection diagnosis. DNA-based techniques are useful because they 
are able to detect the whole bacterial population. Most protocols are based on PCR 
or qPCR assays [63].
To find a suitable target gene on which to base P. aeruginosa detection, 
most protocols have been tested on a variety of bacterial isolates of different 
origins. The oprL gene, encoding a peptidoglycan-associated protein, has long 
been considered as one of the best targets [64–67]. However, its specificity 
was questioned when Anuj and colleagues [68] obtained cross-reactions with 
other species. Notably, the selection of multiple targets is considered as the best 
approach to P. aeruginosa detection, since it excludes false-negative results due 
to mutations in the amplified gene sequences. The gyrB and ecfX genes are two 
other widely used targets. The former gene encodes the DNA gyrase subunit B. 
Tests against several CF P. aeruginosa isolates have identified a species-specific 
internal sequence [69, 70]. The ecfX gene – found in 19 copies/genome – encodes 
a σ factor belonging to the ECF subfamily, which is involved in the synthesis of 
proteins with an extracytoplasmic function and seems to play a role in P. aerugi-
nosa haem uptake and virulence [71]. The gene has been reported to be specific 
of P. aeruginosa and has been used to achieve its detection in environmental as 
well as clinical samples [6, 71]. Further proposed targets are the algD gene [72] 
and some 16 s [73] and 23 s rDNA sequences [74].
After reliable detection, a key issue is direct pathogen quantification in sputum 
samples. Most of the work in this field has been performed after 2010 using specific 
extraction kits and lysis protocols [66, 67, 74–76].
The main drawback of DNA-based approaches is that they do not detect only live 
bacterial cells and may be affected by the presence of dead cells as well as by eDNA 
[77]. An efficient and widely used approach to this problem is to treat samples with 
propidium monoazide before DNA extraction [66]. The dye penetrates the cells via 
damaged walls/membranes and binds their DNA; after photo-activation, binding 
to the nucleic acids prevents DNA polymerase binding, hence DNA amplification 
in PCR assays. Since live cells commonly have an intact wall, they are not affected 
by the dye and only their DNA is detected. The same objective can be achieved with 
other treatments such as ethidium monoazide and DNase [6, 77].
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Despite some drawbacks, DNA-based methods provide additional valuable 
information to the cell culture results when investigating and monitoring P. aeru-
ginosa colonization dynamics in the CF lung [78]. Accordingly, extensive metage-
nomic studies of the CF microbiota have highlighted that persistent cells play a 
major role in infection chronicization and that persistence is favored by alterations 
in bacterial gene expression [79], further stressing the value of molecular tech-
niques in routine diagnostics [80, 81].
Another useful technique capable of providing direct bacterial quantification 
is flow cytometry. Although it has mostly been employed to investigate bacterial 
physiology and metabolic responses [82], efforts to optimize its quantification 
ability have made it suitable for some diagnostic applications [83]. In particular, 
flow cytometry analysis and imaging now enable detection and enumeration of 
non-culturable and intracellular P. aeruginosa cells [84, 85].
Other approaches to detect the whole microbial community of CF lung have 
also been developed and in the last years indirect detection has been also achieved 
by metabolomic methods targeting specific bacterial metabolites as pathogen 
footprints [86].
4.2 Evidence of the presence of VBNC P. aeruginosa in CF sputum
The presence of VBNC P. aeruginosa cells in the CF lung and in particular their 
role in infection recurrence are highly controversial. However, the induction of 
VBNC cells in the CF lung environment currently seems to be the most likely 
explanation for the failure of infection eradication in the presence of a negative 
microbiological diagnosis [6].
The first reports of pathogen persistence in patients with negative sputum 
cultures, published by Schelstraete and Deschaght and colleagues [87], described 
the swift reappearance of the same P. aeruginosa strain, after a brief interval of 
ostensible resolution, in patients treated with eradication therapy. Deschaght and 
co-workers [66] subsequently demonstrated that the pathogen could be detected 
by qPCR much earlier than by culture assays and that qPCR was able to detect a 
high percentage (62%) of non-culturable P. aeruginosa cells in sputum samples from 
patients who had received the first week of antibiotic treatment. A discrepancy 
between culture-based and culture-independent methods has also been reported 
by Le Gall [75] and Héry-Arnaud [76] who advanced the hypothesis of a shift of 
bacterial cells to a non-culturable state. A positive qPCR assay preceding a posi-
tive culture has also been described by McCulloch and colleagues [74] and, more 
recently, by Boutin and co-workers [88].
Our group has carried out extensive work to identify and quantify VBNC P. aeru-
ginosa cells in CF sputum [6]. Combining two previously published ecfX-targeting 
primers we obtained a new amplicon (145 bp) suitable for qPCR. Testing of the new 
primer pair against a panel of 115 P. aeruginosa strains of different origins and other 
Gram-negative bacterial species failed to elicit a cross-reaction, confirming the 
species specificity of the selected target. Moreover – even though the use of a single 
target gene cannot exclude false-negative results due to target mutations [68] – the 
ecfX sequence yielded a positive PCR result in 111/115 (96.6%) of the P. aeruginosa 
strains and the use of a second target gene (gyrB) did not lead to an increase of P. 
aeruginosa detection ([89] unpublished data).
Total DNA was extracted from CF sputum samples using the QIAamp DNA kit 
(Qiagen, Hilden, Germany) and qPCR assays were performed using a SYBR Green 
reaction format. The sensitivity of the protocol combining DNA extraction and 
qPCR was determined by testing P. aeruginosa-free sputum samples inoculated with 
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serial dilutions of log phase P. aeruginosa cultures. Protocol sensitivity was 70 cells/
ml, which is comparable to the sensitivity of TaqMan probe-based qPCR assays 
[90]. Its limit of detection, determined by amplifying serial dilutions of a purified 
ecfX amplicon, was 5.2 x 10−9 ng/reaction, corresponding to about 140 cells/ml in 
the original samples.
eDNA interference was excluded by treating samples with DNase I (18 U) before 
DNA extraction. Preliminary assays were performed using P. aeruginosa-free spu-
tum samples inoculated with 10% live and 90% dead P. aeruginosa cultures. DNase-
treated and untreated aliquots were processed using an in-house crude extraction 
procedure or the QIAamp extraction kit (Figure 3).
The qPCR counts of DNase-treated aliquots always matched the live cell quota 
(10%) of the P. aeruginosa inoculum. As regards the untreated aliquots, they 
corresponded to the whole P. aeruginosa load (100%) when qPCR was performed 
on crude extracts, whereas qPCR performed on DNA extracted with the QIAamp 
kit yielded counts that were comparable to those obtained after DNase pretreat-
ment. This is likely due to the fact that the eDNA of dead P. aeruginosa cells was 
too damaged to be efficiently bound and retained in the extraction column. It can 
thus be assumed that DNA extraction with suitable commercial kits – whether 
alone or combined with DNase treatment – excluded eDNA and provided reliable 
 quantification of live bacterial cells.
We performed the same procedure in 88 CF sputum samples from 55 patients.
The qPCR and culture-based counts were largely comparable (i.e. 78.41% of 
all samples, 43.18% culture-negative and 35.23% culture-positive). Notably, the 
absence of samples that were simultaneously culture-positive and qPCR-negative 
excluded false negatives. The most interesting results were those where the qPCR 
count exceeded the culture-based count (11.40% of samples) and those where 
culture-negative samples showed a qPCR-positive result (10.23%). Given eDNA 
exclusion by DNase treatment and DNA extraction procedure, the discrepancy 
was held to reflect the presence of VBNC P. aeruginosa cells, in line with data 
reported by Deschaght [66], Le Gall [75], McCulloch [74] and Boutin [88]. 
Crucially, 1 and 3 months after the PCR-positive results, the cultures turned 
positive in 2 patients.
Figure 3. 
(Modified from Ref. [6]) Detection of live P. aeruginosa cells in DNase-treated sputum samples. P. aeruginosa 
abundance was quantified by qPCR in CF sputum samples inoculated with 10% live and 90% dead cultures 
with/without DNase I pretreatment. DNA was extracted with a crude extraction procedure or with the 
QIAlamp extraction kit. The qPCR counts were compared to the whole bacterial inoculum.
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5.  Evaluation of the possible role of antibiotics and other stressors 
in triggering VBNC cells and culturable persisters in P. aeruginosa 
biofilms
After demonstrating VBNC P. aeruginosa cells in the lungs of CF patients (6), 
a key issue was to establish the factors that trigger their induction. We therefore 
examined the role of antibiotic treatments and of some environmental stressors 
that are found in the CF lung [51, 58], in selecting and maintaining persister cells, 
particularly VBNC cells.
5.1  Evaluation of the role of sub-MIC of ciprofloxacin and tobramycin in 
inducing VBNC and culturable persistent cells in starved P. aeruginosa  
in vitro biofilms
The possibility of VBNC cell induction by low antibiotic doses was first explored 
by our group in starved S. aureus biofilms. Greater VBNC cell persistence and 
survival were found in starved cultures exposed to vancomycin and quinupristin/
dalfopristin than in those subjected to starvation alone [91].
Similar experiments were subsequently performed to test VBNC cell induction 
in P. aeruginosa biofilms exposed to starvation, alone or combined with subinhibi-
tory (1/4 x MIC) concentrations of ciprofloxacin or tobramycin [92], which are the 
most widely used treatments for P. aeruginosa lung infection [39, 93]. Biofilms of 
the laboratory strain P. aeruginosa PAO1 and the CF isolate P. aeruginosa C24 were 
developed in rich medium in 35 mm petri dishes for 48 h at 37°C and then subcul-
tured in non-nutrient (NN) broth, alone or supplemented with sub-MIC concentra-
tions of ciprofloxacin or tobramycin for 170 days. The medium was refreshed once a 
week. Samples were evaluated at 60, 75, 90, 120, 135, 150 and 170 days. The biofilm 
content in VBNC cells was determined as follows:
• the culturable population was quantified by plate counts performed on 
cystine lactose electrolyte-deficient (CLED) agar after incubation for 24, 28 
and 72 h at 37°C;
• total viable cells (TVCs) were expressed as the average of the counts obtained 
from ecfX-qPCR and flow cytometry assays after live/dead staining using 
SYBR Green 1x and propidium iodide 40 μg/ml;
• the number of VBNC cells was determined as the difference between TVCs and 
culturable cells (only differences ≥0.5 log were considered).
The results are reported in Figure 4 and are expressed as percentage of TVCs.
Unlike the S. aureus biofilms, a culturable P. aeruginosa subpopulation, which 
can be defined as triggered persisters, was detected throughout the experiment. 
A VBNC subpopulation also developed and was more abundant in presence 
of the antibiotics. In particular, a subset of VBNC P. aeruginosa PAO1 cells was 
detected in all conditions and gradually declined in starved and ciprofloxacin-
exposed biofilms; in contrast, the VBNC subpopulation triggered by sub-MIC 
tobramycin exceeded 90% of TVCs until the end of the experiment. In P. aerugi-
nosa C24, starvation alone induced a discontinuous VBNC subpopulation; starva-
tion and ciprofloxacin triggered a persister population only between 75 and 
135 days; and starvation and tobramycin induced a constant VBNC population 
whose abundance was similar to the one determined in the PAO1 strain at the end 
of the experiment.
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These data suggest that sub-MIC concentrations of tobramycin (not ciprofloxacin) 
play a strong role in inducing VBNC P. aeruginosa and are in line with previous reports 
of the contribution of protein synthesis inhibitors [94] and aminoglycosides [95] to 
VBNC cell induction. The demonstration of the role of toxin-antitoxin modules [96] 
and ribosome hibernation [3] in persisters development, exerted via a reduction of 
protein synthesis, further supports the observed behavior of tobramycin.
After documenting the role of subinhibitory drug concentrations in VBNC cell 
induction and maintenance, we examined the effectiveness of high antibiotic concen-
trations on P. aeruginosa biofilm eradication by evaluating the abundance of persistent 
and VBNC cells in mature P. aeruginosa PAO1 biofilms exposed to 1000 x MIC/100 x 
MBEC (minimal biofilm eradication concentration) tobramycin for 24 h (Figure 5).
Figure 4. 
(Modified from Ref. [92]). VBNC P. aeruginosa cell abundance in starved biofilms exposed to sub-MIC antibiotic 
concentrations. The VBNC cell subpopulation was assessed at specific time points in P. aeruginosa PAO1 (A) and 
C24 (B) biofilms exposed to starvation (NN) or starvation+ ¼ x MIC ciprofloxacin (NN + CIP) or tobramycin 
(NN + TOB). VBNC cells were the difference between total viable cells (TVCs) and plate counts (only differences 
≥0.5 log were considered). Cell abundance was compared in the three stress conditions. * = p < 0.05, ** = p < 0.001.
Figure 5. 
Biofilm persistence to tobramycin treatment. 24-hour-old P. aeruginosa PAO1 biofilms were exposed for 24 h to 
tobramycin 1000 x MIC and assessed for their content in culturable persisters and VBNC cells before and after 
antibiotic treatment. Persisters were determined by plate count (PC), whereas total viable cells (TVCs) were 
determined by ecfX-qPCR and live/dead flow cytometry. The VBNC population was the difference between 
TVCs and PCs. The results are given as the average of three biological replicates ± standard deviation.
Pseudomonas aeruginosa - Biofilm Formation, Infections and Treatments
12
As expected, the high tobramycin concentrations chiefly affected the culturable 
population, which showed a reduction >4 log, whereas the TVC counts showed a 
2 log reduction, highlighting the presence of more than 1 x 107 VBNC cells/ml after 
24-hours exposure to 1000 x MIC tobramycin.
5.2  Evaluation of the possible involvement of additional stressors found in the 
CF lung
Finally, we examined the possible contribution of further environmental factors – 
especially the high salinity and metabolite accumulation that are found in the CF lung 
[51, 58], − in the induction of persistent and VBNC P. aeruginosa cells.
Culturable cells and TVCs were counted as described above in P. aeruginosa PAO1 
biofilms grown for 7 days in Luria Bertani (LB) broth, alone or added with 13 g/l NaCl. 
The counts were compared to those of a mature 24-hour-old biofilm (Figure 6).
As shown in the diagram, P. aeruginosa biofilms tolerate and adapt to the high 
salinity found in the CF lung, since exposure to this stressor for 7 days failed to 
induce a significant difference in culturable and VBNC cell amount compared 
to the control condition. In contrast, the plate counts demonstrated a difference 
of 1 log between 7-day-old and 24-hour-old LB biofilms, whereas the number of 
TVCs at the two time points was not significantly different. This indicates a shift 
of P. aeruginosa cells to the VBNC state in biofilms grown for 7 days in LB medium, 
where bacterial metabolites accumulate. Most likely, nutrient reduction and waste 
accumulation induce a major shift to the persistent state, as also demonstrated for 
the VBNC cells in biofilms maintained in NN broth.
6. Conclusions
The generation of persistent cell subpopulations is a bacterial survival strategy 
against adverse environmental conditions [2]. Whereas stochastic persisters are 
rare, external stressors can convert most bacterial population into persistent cells [45]. 
Figure 6. 
Induction of VBNC P. aeruginosa cells in biofilms exposed to environmental stress factors. P. aeruginosa PAO1 
biofilms were grown in Luria Bertani broth, with metabolite accumulation (MA T7) or in LB + 13 g/l NaCl 
for 7 days (NaCl T7). Culturable cells were determined by plate count (PC) and total viable cells (TVCs) were 
determined by qPCR/flow cytometry assays. VBNC cells were the difference between TVCs and culturable cells. 
These values were compared to those determined in a 24-hour-old biofilm grown in Luria Bertani (LB) broth. 
The results are average of three biological replicates ± standard deviation.
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In infectious biofilms, a combination of stress factors can induce the development 
of persistent forms which can trigger infection recurrence. This is a cause of special 
concern in P. aeruginosa CF lung infection, where VBNC cells undermine treat-
ment and hamper microbiological diagnosis, which is still routinely performed by 
culture-based assays. A routine diagnostic workup including culture-independent 
approaches should thus be urgently adopted.
The evidence described in this chapter demonstrates that VBNC P. aeruginosa 
cells are found in sputum samples from CF patients and that several months after 
a culture-negative and qPCR-positive assay some patients experience infection 
recurrence and have culture-positive sputum samples. These data also highlight the 
reliability of qPCR in detecting the whole bacterial population, including the phe-
notypic variants that are missed by culture-based assays. Notably, flow cytometry 
has demonstrated the accuracy of the ecfX-targeting qPCR protocol in detecting all 
viable P. aeruginosa cells and can provide a sound alternative for routine  monitoring 
of the infection. Together, qPCR and flow cytometry supply a clear picture of 
P. aeruginosa population dynamics in the lungs of CF patients with intermittent and 
chronic infection and can be harnessed to monitor the effectiveness of the antibiotic 
therapy and to foster the development of new eradication treatments.
The two techniques have enabled us to gain insight into the role of antibiotics in 
VBNC cell development and infection persistence. Notably, whereas high antibiotic 
doses can select persistent subpopulations, subinhibitory concentrations – which 
are found in the CF lung between treatment cycles and in the deepest biofilm layers 
[51, 58] – can stimulate the development of persistent phenotypic variants, including 
VBNC cells [53]. Besides the fact that starvation proved to be a necessary condition 
for VBNC cell induction in our in vitro biofilms, our findings highlight a different 
behavior of tobramycin and ciprofloxacin. Although large amounts of VBNC cells 
were induced in all test conditions over the first 120 days, their number was main-
tained more consistently in presence of tobramycin, whereas ciprofloxacin exerted a 
discontinuous effect similar to the one of starvation alone. These findings can partly 
be explained by the ability of tobramycin to act as a signal molecule that interferes 
with QS signals, thus modulating gene expression in biofilm-growing P. aeruginosa 
[58], and by its adverse effect on protein synthesis via ribosome binding [3].
In conclusion, more detailed information on the main gene pathways and per-
sistence regulators and on the effects of different antibiotics is essential to meet the 
challenge of antibiotic-resilient P. aeruginosa infectious biofilms and the eradication 
of CF lung infection.
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